Molecular structure of Purvalanol B, CAS Number: 212844-54-7
Purvalanol B (CAS 212844-54-7)
Alternate Names:
NG 95
Application:
Purvalanol B is a cyclin-dependent kinase inhibitor
CAS Number:
212844-54-7
Purity:
>95%
Molecular Weight:
432.90
Molecular Formula:
C20H25ClN6O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Purvalanol B may act to be a Cdk (cyclin-dependent kinase) inhibitor. IC50 values are 6, 6, 9, > 10,000, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively. This compound has also been shown to have antiproliferative properties, mediated by p42/p44 MAPK. Purvalanol B is an inhibitor of Cdk6 and Cdk9. It possess anti-inflammatory, anti-tumor, anti-viral, and anti-microbial properties.
Purvalanol B (CAS 212844-54-7) References
- Protein kinases as targets for anti-parasitic chemotherapy. | Doerig, C. 2004. Biochim Biophys Acta. 1697: 155-68. PMID: 15023358
- Ligand binding affinity determined by temperature-dependent circular dichroism: cyclin-dependent kinase 2 inhibitors. | Mayhood, TW. and Windsor, WT. 2005. Anal Biochem. 345: 187-97. PMID: 16140252
- Crystal structures of active SRC kinase domain complexes. | Breitenlechner, CB., et al. 2005. J Mol Biol. 353: 222-31. PMID: 16168436
- VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. | Ringer, L., et al. 2010. Cancer Biol Ther. 10: 320-5. PMID: 20574155
- Simultaneous detection of intracellular target and off-target binding of small molecule cancer drugs at nanomolar concentrations. | Glauner, H., et al. 2010. Br J Pharmacol. 160: 958-70. PMID: 20590591
- Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells. | Yenugonda, VM., et al. 2011. Bioorg Med Chem. 19: 2714-25. PMID: 21440449
- VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. | Ringer, L., et al. 2011. Cancer Biol Ther. 12: 818-26. PMID: 21885916
- Effects of cyclin-dependent kinase inhibitor Purvalanol B application on protein expression and developmental progression in intra-erythrocytic Plasmodium falciparum parasites. | Bullard, KM., et al. 2015. Malar J. 14: 147. PMID: 25879664
- Changes in cellular signaling proteins in extracts from A549, H460, and U2OS cells treated with cisplatin or docetaxel. | Petrovic, V., et al. 2017. Data Brief. 12: 18-21. PMID: 28367485
Inhibitor of:
1300002E11Rik, 4933404M19Rik, ACAT-2, APC4, AUNIP, C18orf15, C1orf96, C20orf19, Cables2, CASC5, CCDC52, Cdc2, Cdk2, Cdk5, Cdk6, Cdk9, CENP-F, CENP-R, CINP, cyclin M2, Enzyme, HEI-C, HTF9C, INCA1, INSC, KIAA0284, Mad 3, MAD2L1BP, MASTL, MPHOSPH8, NUDE1, Sgo2, Speriolin, and VRK1.Activator of:
C1orf96, CCDC53, CCNJL, Cdc28, CdcA4, Clb1, Dyrk2, Kizuna_Plk1s1, LIP1, Mat1, Mps1, and ZYG11A.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Purvalanol B, 10 mg | sc-361300 | 10 mg | $199.00 | |||
Purvalanol B, 50 mg | sc-361300A | 50 mg | $846.00 |